J Korean Neuropsychiatr Assoc.
2022 Nov;61(4):243-253. 10.4306/jknpa.2022.61.4.243.
“Drugs of Abuse” as a “New Antidepressant”: - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential
- Affiliations
-
- 1Department of Psychiatry, Seoul National University Hospital, Seoul, Korea
- 2Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul, Korea
- 3Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, Korea
- 4Clinical Research Institute, Seoul National University Hospital, Seoul, Korea
- KMID: 2536663
- DOI: http://doi.org/10.4306/jknpa.2022.61.4.243
Abstract
- Drugs once classified as ‘substances of abuse’ are now drawing attention in the field of psychiatry as ‘new antidepressants’ for the management of treatment-resistant depression (TRD). Intranasal esketamine was approved by the Food and Drug Administration (FDA) for TRD and stimulants are being used as adjuvant therapy. Clinical studies on the use of cannabinoids, opiates, and psilocybin for depression are currently being conducted. However, even as they are being evaluated for their effectiveness, concern for their abuse potential is growing. In this article, the characteristics of ‘drugs of abuse’ that are approved or being developed as ‘new antidepressants’ are reviewed. Their historical background as mood-enhancers, pharmacological mechanisms, antidepressant effects, and risk of abuse are also discussed.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Interaction Effect of Childhood Abuse History and Suicidality on 12-Month Antidepressant Response in Patients With Depressive Disorder
- A Critical View on New and Future Antidepressants
- The Antidepressant Effects and Clinical Implication of Ketamine
- Antidepressant Discontinuation Syndrome
- Role of p11 (S100A10) in Depression and Antidepressant Effects
